Ge Long Hui·2026-01-20 10:06Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the National Medical Products Administration for its self-developed B023 cell injection, a Class I innovative biological product aimed at treating inoperable locally advanced or metastatic solid tumors that have failed standard treatments [1] Group 1: Product Development - The B023 cell injection is developed by Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd [1] - The core component of B023 is invariant natural killer T (iNKT) cells, which are a type of non-classical T cell with a constant T cell receptor (TCR) [1] - iNKT cells can be used in allogeneic applications without causing graft-versus-host disease (GvHD) due to the lack of polymorphism in the CD1d molecule in the human population [1] Group 2: Financial Investment - As of the date of the announcement, the total research and development investment for the B023 project has reached approximately 39.2584 million RMB [1]